High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm
- PMID: 24713591
- DOI: 10.1038/clpt.2014.79
High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm
Abstract
High-density-lipoprotein cholesterol (HDL-C) has been identified in population studies as an independent inverse predictor of cardiovascular events. Although the causal nature of this association has been questioned, HDL and its major protein, apolipoprotein (apo)A1, have been shown to prevent and reverse atherosclerosis in animal models. In addition, HDL and apoA1 have several putatively atheroprotective functions, such as the ability to promote efflux of cholesterol from macrophages in the artery wall, inhibit vascular inflammation, and enhance endothelial function. Therefore, HDL-C and apoA1 have been investigated as therapeutic targets for coronary heart disease. However, recent clinical trials with drugs that raise HDL-C, such as niacin and inhibitors of cholesteryl ester transfer protein, have been disappointing. Here, we review the current state of the science regarding HDL as a therapeutic target.
Similar articles
-
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.J Am Coll Cardiol. 2006 Feb 7;47(3):492-9. doi: 10.1016/j.jacc.2005.09.042. Epub 2006 Jan 18. J Am Coll Cardiol. 2006. PMID: 16458126 Review.
-
Beginning to understand high-density lipoproteins.Endocrinol Metab Clin North Am. 2014 Dec;43(4):913-47. doi: 10.1016/j.ecl.2014.08.001. Endocrinol Metab Clin North Am. 2014. PMID: 25432389 Review.
-
Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.Biochimie. 2014 Jan;96:56-66. doi: 10.1016/j.biochi.2013.08.027. Epub 2013 Sep 5. Biochimie. 2014. PMID: 24012775 Review.
-
Targeting high-density lipoproteins: update on a promising therapy.Arch Cardiovasc Dis. 2013 Nov;106(11):601-11. doi: 10.1016/j.acvd.2013.06.052. Epub 2013 Sep 25. Arch Cardiovasc Dis. 2013. PMID: 24074699
-
High-density lipoprotein therapeutics and cardiovascular prevention.J Clin Lipidol. 2010 Sep-Oct;4(5):411-9. doi: 10.1016/j.jacl.2010.08.004. Epub 2010 Aug 17. J Clin Lipidol. 2010. PMID: 21122685 Review.
Cited by
-
Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis.Curr Ther Res Clin Exp. 2018 Jul 23;89:1-6. doi: 10.1016/j.curtheres.2018.07.001. eCollection 2018. Curr Ther Res Clin Exp. 2018. PMID: 30128057 Free PMC article.
-
Immunochemical Approach for Monitoring of Structural Transition of ApoA-I upon HDL Formation Using Novel Monoclonal Antibodies.Sci Rep. 2017 Jun 7;7(1):2988. doi: 10.1038/s41598-017-03208-8. Sci Rep. 2017. PMID: 28592796 Free PMC article.
-
What does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport?Curr Opin Lipidol. 2015 Oct;26(5):420-5. doi: 10.1097/MOL.0000000000000211. Curr Opin Lipidol. 2015. PMID: 26218419 Free PMC article. Review.
-
Impact of Platelet-to-HDL-Cholesterol Ratio on Long-Term Mortality in Coronary Artery Disease Patients with or Without Type 2 Diabetes: Insights from a Chinese Multicenter Cohort.J Inflamm Res. 2024 May 6;17:2731-2744. doi: 10.2147/JIR.S458950. eCollection 2024. J Inflamm Res. 2024. PMID: 38737110 Free PMC article.
-
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.Ann Clin Biochem. 2019 May;56(3):338-356. doi: 10.1177/0004563219827620. Epub 2019 Mar 19. Ann Clin Biochem. 2019. PMID: 30889974 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous